Brian T. Andrews
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Brian T. Andrews has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
Stefani C. Fontana
Department of Plastic Surgery
5 shared publications- Terry C. Yin
University of Iowa Carver College of Medicine, IA, USA
5 shared publications Wojciech H. Przylecki
Department of Plastic Surgery, University of Kansas Medical Center, Kansas City, KS, USA
5 shared publicationsNiaman Nazir
Department of Preventative Medicine and Health, University of Kansas Medical Center, Kansas City, Kansas
4 shared publicationsPaul J. Camarata
Department of Neurosurgery, University of Kansas Medical Center, Kansas City, KS, USA
4 shared publicationsRandolph J. Nudo
University of Kansas Medical Center, Kansas City, KS, USA
4 shared publications
Latest Publications
- 7 October 2026
- Published by SAGE Publications in Face
- Vol. 7 (4) , 691-697
Ovine Pilot Study Utilizing PMIS-miR-200a DNA Plasmid Gene Therapy for Regenerative Cranioplasty
Background: Reliable autologous regeneration of cranial bone remains an important unmet objective in craniomaxillofacial reconstruction. MicroRNA (miR)-based gene therapy, including inhibition of specific miRs, may provide a regenerative strategy. Methods: Two young adult male sheep were used to evaluate cranial bone regeneration using a plasmid-based microRNA inhibitor system ( PMIS ) targeting miR-200a . Variables included collagen matrix versus decellularized bone scaffolds and naked plasmid DNA versus PEG-peptide nanoparticle delivery. Results: Gross examination at 6 weeks demonstrated osseous regeneration in both 15 mm circular full-thickness calvarial defects treated with PMIS-miR-200a delivered on either a collagen sponge or a decellularized bone scaffold. Microcomputed tomography (µCT) and histologic analyses demonstrated new bone formation in both defects. In the second sheep, the 15 mm defect treated with PMIS-miR-200a delivered by PEG-peptide nanoparticles on a collagen sponge exhibited greater new bone fill than the empty-vector control defect. A larger 30 × 15 mm defect treated with PMIS-miR-200a delivered by the same nanoparticle system on a collagen sponge demonstrated peripheral new bone formation at 12 weeks. Conclusion: These pilot findings provide preliminary evidence that PMIS-miR-200a gene therapy can promote cranial bone regeneration in an ovine model. Adequately powered studies are required to optimize dose, scaffold, delivery system, and follow-up interval and to establish safety, efficacy, and mechanistic target engagement.
- 7 October 2026
- Published by SAGE Publications in Face
- Vol. 7 (4) , 691-697
Ovine Pilot Study Utilizing PMIS-miR-200a DNA Plasmid Gene Therapy for Regenerative Cranioplasty
Background: Reliable autologous regeneration of cranial bone remains an important unmet objective in craniomaxillofacial reconstruction. MicroRNA (miR)-based gene therapy, including inhibition of specific miRs, may provide a regenerative strategy. Methods: Two young adult male sheep were used to evaluate cranial bone regeneration using a plasmid-based microRNA inhibitor system ( PMIS ) targeting miR-200a . Variables included collagen matrix versus decellularized bone scaffolds and naked plasmid DNA versus PEG-peptide nanoparticle delivery. Results: Gross examination at 6 weeks demonstrated osseous regeneration in both 15 mm circular full-thickness calvarial defects treated with PMIS-miR-200a delivered on either a collagen sponge or a decellularized bone scaffold. Microcomputed tomography (µCT) and histologic analyses demonstrated new bone formation in both defects. In the second sheep, the 15 mm defect treated with PMIS-miR-200a delivered by PEG-peptide nanoparticles on a collagen sponge exhibited greater new bone fill than the empty-vector control defect. A larger 30 × 15 mm defect treated with PMIS-miR-200a delivered by the same nanoparticle system on a collagen sponge demonstrated peripheral new bone formation at 12 weeks. Conclusion: These pilot findings provide preliminary evidence that PMIS-miR-200a gene therapy can promote cranial bone regeneration in an ovine model. Adequately powered studies are required to optimize dose, scaffold, delivery system, and follow-up interval and to establish safety, efficacy, and mechanistic target engagement.
- 6 September 2026
- Published by SAGE Publications in Face
- Vol. 7 (4) , 698-708
Pilot Study: Zwitterionic Conditioning of the Decompressive Craniectomy Site for Early Cranioplasty Feasibility
Background: Early cranioplasty after decompressive craniectomy (DC) for moderate-to-severe traumatic brain injury (TBI) improves functional recovery. However, patient candidacy is limited by persistent brain swelling, soft-tissue inflammation, and fibrotic wound remodeling. Zwitterion (ZI) hydrogels exhibit antifouling and anti-inflammatory properties that may improve the DC wound microenvironment. We hypothesize that ZI hydrogel application at the DC site attenuates TBI-associated biomarkers and improves motor recovery in rodents. Methods: Adult CD1 mice were randomized to sham, TBI, TBI/DC, or TBI/DC/ZI hydrogel (hereafter referred to as ZI hydrogel) groups to quantify serum GFAP, NfL, and UCH-L1 by ELISA at 24 hours. Adult Long Evans rats underwent the same interventions to assess ZI-dependent motor recovery using beam-walk time and limb slips normalized to baseline at days 7 and 14. Results: TBI significantly elevated serum GFAP and UCH-L1 versus sham ( P = .0014 and .0471). Both TBI/DC and ZI hydrogel normalized GFAP, NfL, and UCH-L1 to sham-comparable levels; however, only ZI hydrogel significantly reduced NfL ( P = .0256) and UCH-L1 ( P = .0200) versus TBI/DC. Beam-walk testing showed no significant post-TBI motor deterioration in ZI hydrogel rats, whereas TBI/DC rats exhibited persistent deficits in crossing time and limb slips at days 7 and 14. Conclusions: ZI hydrogel application at the time of DC reduced TBI-specific serum biomarkers and improved motor recovery in a rodent moderate-to-severe TBI model. These findings support further investigation of ZI hydrogels as adjunctive therapy to attenuate neuroinflammation and facilitate earlier, safer cranioplasty after DC.
- 6 September 2026
- Published by SAGE Publications in Face
- Vol. 7 (4) , 698-708
Pilot Study: Zwitterionic Conditioning of the Decompressive Craniectomy Site for Early Cranioplasty Feasibility
Background: Early cranioplasty after decompressive craniectomy (DC) for moderate-to-severe traumatic brain injury (TBI) improves functional recovery. However, patient candidacy is limited by persistent brain swelling, soft-tissue inflammation, and fibrotic wound remodeling. Zwitterion (ZI) hydrogels exhibit antifouling and anti-inflammatory properties that may improve the DC wound microenvironment. We hypothesize that ZI hydrogel application at the DC site attenuates TBI-associated biomarkers and improves motor recovery in rodents. Methods: Adult CD1 mice were randomized to sham, TBI, TBI/DC, or TBI/DC/ZI hydrogel (hereafter referred to as ZI hydrogel) groups to quantify serum GFAP, NfL, and UCH-L1 by ELISA at 24 hours. Adult Long Evans rats underwent the same interventions to assess ZI-dependent motor recovery using beam-walk time and limb slips normalized to baseline at days 7 and 14. Results: TBI significantly elevated serum GFAP and UCH-L1 versus sham ( P = .0014 and .0471). Both TBI/DC and ZI hydrogel normalized GFAP, NfL, and UCH-L1 to sham-comparable levels; however, only ZI hydrogel significantly reduced NfL ( P = .0256) and UCH-L1 ( P = .0200) versus TBI/DC. Beam-walk testing showed no significant post-TBI motor deterioration in ZI hydrogel rats, whereas TBI/DC rats exhibited persistent deficits in crossing time and limb slips at days 7 and 14. Conclusions: ZI hydrogel application at the time of DC reduced TBI-specific serum biomarkers and improved motor recovery in a rodent moderate-to-severe TBI model. These findings support further investigation of ZI hydrogels as adjunctive therapy to attenuate neuroinflammation and facilitate earlier, safer cranioplasty after DC.
- 6 April 2026
- Published by SAGE Publications in The Cleft Palate Craniofacial Journal
- Vol. 63 (12) , 4281-4288
Feasibility of Craniofacial Vascular Lymph Node Transfer for Augmented Glymphatic Drainage in Rodents
Objective: Glymphatic dysfunction contributes to CNS pathobiology, including neurodegeneration. We hypothesized that vascularized lymph node transfer (VLNT) augments CSF-interstitial solute clearance and could be translated as a surgical therapy analogous to lymphedema surgery. Design: Twenty Long-Evans rats were randomized to 3 arms: (1) Craniectomy Control (hemi-craniectomy; VLNT sampled in situ, nontransposed), (2) VLNT Control (intact calvarium; VLNT without craniectomy), and (3) Experimental (hemi-craniectomy + VLNT). One week postsurgery, Evans Blue dye (EBD) was injected into the cisterna magna; at 4 h, right/left cerebrum and cerebellum lysates underwent spectrophotometry at 608 nm. VLNT viability was verified by podoplanin (PDPN) immunohistochemistry. Main Outcome Measure(s): Two-way ANOVA showed significantly reduced EBD in Experimental vs controls: left hemisphere vs Craniectomy Control P = .0011 and vs VLNT Control P = .0200; cerebellum vs both controls P < .0001. The right hemisphere was lower vs Craniectomy Control ( P = .0255) and not different from VLNT Control ( P = .3878). VLNT-tissue lysates were higher in Experimental than Craniectomy Control ( P = .0028) and VLNT Control ( P = .0289), consistent with active lymphatic uptake. PDPN staining confirmed robust lymphatic endothelial labeling in cross-sectional and longitudinal planes. Results: VLNT significantly enhances putative glymphatic efflux following decompressive craniectomy, recapitulating the therapeutic principle of lymphatic bypass in lymphedema. Conclusion: These proof-of-concept data support VLNT as a candidate surgical intervention for glymphatic insufficiency and neurodegenerative (ND)-relevant proteostasis/clearance failure. Future studies will optimize timing, node vascularization strategies, and longitudinal outcome measures.
- 6 April 2026
- Published by SAGE Publications in The Cleft Palate Craniofacial Journal
- Vol. 63 (12) , 4281-4288
Feasibility of Craniofacial Vascular Lymph Node Transfer for Augmented Glymphatic Drainage in Rodents
Objective: Glymphatic dysfunction contributes to CNS pathobiology, including neurodegeneration. We hypothesized that vascularized lymph node transfer (VLNT) augments CSF-interstitial solute clearance and could be translated as a surgical therapy analogous to lymphedema surgery. Design: Twenty Long-Evans rats were randomized to 3 arms: (1) Craniectomy Control (hemi-craniectomy; VLNT sampled in situ, nontransposed), (2) VLNT Control (intact calvarium; VLNT without craniectomy), and (3) Experimental (hemi-craniectomy + VLNT). One week postsurgery, Evans Blue dye (EBD) was injected into the cisterna magna; at 4 h, right/left cerebrum and cerebellum lysates underwent spectrophotometry at 608 nm. VLNT viability was verified by podoplanin (PDPN) immunohistochemistry. Main Outcome Measure(s): Two-way ANOVA showed significantly reduced EBD in Experimental vs controls: left hemisphere vs Craniectomy Control P = .0011 and vs VLNT Control P = .0200; cerebellum vs both controls P < .0001. The right hemisphere was lower vs Craniectomy Control ( P = .0255) and not different from VLNT Control ( P = .3878). VLNT-tissue lysates were higher in Experimental than Craniectomy Control ( P = .0028) and VLNT Control ( P = .0289), consistent with active lymphatic uptake. PDPN staining confirmed robust lymphatic endothelial labeling in cross-sectional and longitudinal planes. Results: VLNT significantly enhances putative glymphatic efflux following decompressive craniectomy, recapitulating the therapeutic principle of lymphatic bypass in lymphedema. Conclusion: These proof-of-concept data support VLNT as a candidate surgical intervention for glymphatic insufficiency and neurodegenerative (ND)-relevant proteostasis/clearance failure. Future studies will optimize timing, node vascularization strategies, and longitudinal outcome measures.
- 15 July 2025
- Published by SAGE Publications in The Cleft Palate Craniofacial Journal
- Vol. 63 (7) , 1968-1973
TBI Biomarker Improvements Following Rodent Decompressive Craniectomy and Motor Outcome Validation of Early Cranioplasty
Background: Decompressive craniectomy (DC) is a venerable clinical tool to manage moderate-to-severe traumatic brain injury (TBI). The utility of recently approved neuroinflammatory biomarkers glial fibrillary acidic protein ( GFAP ) and ubiquitin C-terminal hydrolase-L1 ( UCH-L1 ) is unclear in DC patients as does the timing of cranioplasty to repair/restore the missing cranial bone. We hypothesize that DC diminishes acute neuroinflammatory biomarkers GFAP and UCH-L1 and that early cranioplasty improves motor recovery following DC in moderate-to-severe TBI. Methods: A rodent TBI paradigm utilized a “hit-and-run” closed cortical impact to induce moderate-to-severe trauma. GFAP and UCH-L1 were quantified in CD1 mice (ELISA) in sham, TBI, and TBI-DC. Concurrently, Long-Evans rats received early or delayed alloplastic cranioplasty, with beam walk to assess motor proficiency. A 2-way ANOVA with Dunnett's post hoc determined group-level differences. Results: GFAP and UCH-L1 were elevated in TBI at post-TBI day 1 (GFAP: P = .0233; UCH-L1: P = .0005) and partially elevated in TBI-DC (GFAP: P = .0603; UCH-L1: P = .0326). By day 7, biomarker levels converged ( P > .05), indicating acute neuroinflammation resolution. Early cranioplasty maintained near-sham motor performance at day 4 ( P = .9925). Absence of cranioplasty (TBI-DC) produced persistent deficits (day 4: P = .0319; day 11: P = .0069; day 18: P = .0112). Late cranioplasty yielded improvement, achieving near-sham results by day 11 or post-cranioplasty day 5 ( P = .9166). Conclusions: In this moderate-to-severe TBI model, DC significantly mitigates astroglial and neuronal biomarker expression. Timely cranioplasty further augments motor recovery, underscoring its relevance for optimizing neurological convalescence following decompressive surgery in acute TBI management.
- 15 July 2025
- Published by SAGE Publications in The Cleft Palate Craniofacial Journal
- Vol. 63 (7) , 1968-1973
TBI Biomarker Improvements Following Rodent Decompressive Craniectomy and Motor Outcome Validation of Early Cranioplasty
Background: Decompressive craniectomy (DC) is a venerable clinical tool to manage moderate-to-severe traumatic brain injury (TBI). The utility of recently approved neuroinflammatory biomarkers glial fibrillary acidic protein ( GFAP ) and ubiquitin C-terminal hydrolase-L1 ( UCH-L1 ) is unclear in DC patients as does the timing of cranioplasty to repair/restore the missing cranial bone. We hypothesize that DC diminishes acute neuroinflammatory biomarkers GFAP and UCH-L1 and that early cranioplasty improves motor recovery following DC in moderate-to-severe TBI. Methods: A rodent TBI paradigm utilized a “hit-and-run” closed cortical impact to induce moderate-to-severe trauma. GFAP and UCH-L1 were quantified in CD1 mice (ELISA) in sham, TBI, and TBI-DC. Concurrently, Long-Evans rats received early or delayed alloplastic cranioplasty, with beam walk to assess motor proficiency. A 2-way ANOVA with Dunnett's post hoc determined group-level differences. Results: GFAP and UCH-L1 were elevated in TBI at post-TBI day 1 (GFAP: P = .0233; UCH-L1: P = .0005) and partially elevated in TBI-DC (GFAP: P = .0603; UCH-L1: P = .0326). By day 7, biomarker levels converged ( P > .05), indicating acute neuroinflammation resolution. Early cranioplasty maintained near-sham motor performance at day 4 ( P = .9925). Absence of cranioplasty (TBI-DC) produced persistent deficits (day 4: P = .0319; day 11: P = .0069; day 18: P = .0112). Late cranioplasty yielded improvement, achieving near-sham results by day 11 or post-cranioplasty day 5 ( P = .9166). Conclusions: In this moderate-to-severe TBI model, DC significantly mitigates astroglial and neuronal biomarker expression. Timely cranioplasty further augments motor recovery, underscoring its relevance for optimizing neurological convalescence following decompressive surgery in acute TBI management.
- 14 May 2025
- Published by SAGE Publications in Face
- Vol. 6 (3) , 518-525
Pilot Rodent Study Utilizing Targeted Dexamethasone Polymeric Fibers in Place of Two-Stage Decompressive Craniectomy and Cranioplasty
Background: Traumatic brain injury (TBI) poses significant challenges due to its complex pathology with cerebral edema being a critical complication. Moderate-to-severe TBI is most often managed with a surgical intervention utilizing a two-stage decompressive craniectomy (DC) and cranioplasty. This study investigates a novel, minimally invasive approach using biodegradable polymer fibers for targeted, sustained dexamethasone (DEX) delivery as a minimally invasive surgical alternative. Method: Adult male Long Evans rats (n = 12) were used to assess the efficacy of intraparenchymal sustained-release DEX fibers for moderate-to-severe focal TBI. Rats were randomized to receive DEX fibers at the injury site or a single intramuscular DEX dose. Functional recovery was evaluated via skilled reaching tasks, and systemic DEX levels were monitored using venous sampling and high-performance liquid chromatography. Statistical analysis confirmed the potential of targeted DEX delivery for enhancing TBI recovery ( P < .05). Results: Motor recovery following TBI was evaluated using the skilled reaching task, with Group #1 (targeted DEX fiber placement) showing significantly higher post-TBI recovery scores compared to Group #2 (systemic intramuscular DEX) at all timepoints ( P < .0001). Longitudinal analysis confirmed sustained DEX release in Group #1 with minimal systemic absorption, whereas Group #2 exhibited negligible systemic DEX levels beyond 48 hours. These results demonstrate the efficacy of targeted DEX delivery in enhancing neurobehavioral recovery while minimizing systemic exposure, addressing limitations of conventional systemic therapies in TBI management. Conclusion: TBI remains a major global health challenge with limited treatment options and significant morbidity and mortality. This study demonstrates that intraparenchymal sustained-release DEX fibers improve motor recovery and mitigate systemic side effects compared to systemic corticosteroid use. These findings highlight the potential for targeted, localized DEX therapy as a minimally invasive alternative to DC and cranioplasty.
- 14 May 2025
- Published by SAGE Publications in Face
- Vol. 6 (3) , 518-525
Pilot Rodent Study Utilizing Targeted Dexamethasone Polymeric Fibers in Place of Two-Stage Decompressive Craniectomy and Cranioplasty
Background: Traumatic brain injury (TBI) poses significant challenges due to its complex pathology with cerebral edema being a critical complication. Moderate-to-severe TBI is most often managed with a surgical intervention utilizing a two-stage decompressive craniectomy (DC) and cranioplasty. This study investigates a novel, minimally invasive approach using biodegradable polymer fibers for targeted, sustained dexamethasone (DEX) delivery as a minimally invasive surgical alternative. Method: Adult male Long Evans rats (n = 12) were used to assess the efficacy of intraparenchymal sustained-release DEX fibers for moderate-to-severe focal TBI. Rats were randomized to receive DEX fibers at the injury site or a single intramuscular DEX dose. Functional recovery was evaluated via skilled reaching tasks, and systemic DEX levels were monitored using venous sampling and high-performance liquid chromatography. Statistical analysis confirmed the potential of targeted DEX delivery for enhancing TBI recovery ( P < .05). Results: Motor recovery following TBI was evaluated using the skilled reaching task, with Group #1 (targeted DEX fiber placement) showing significantly higher post-TBI recovery scores compared to Group #2 (systemic intramuscular DEX) at all timepoints ( P < .0001). Longitudinal analysis confirmed sustained DEX release in Group #1 with minimal systemic absorption, whereas Group #2 exhibited negligible systemic DEX levels beyond 48 hours. These results demonstrate the efficacy of targeted DEX delivery in enhancing neurobehavioral recovery while minimizing systemic exposure, addressing limitations of conventional systemic therapies in TBI management. Conclusion: TBI remains a major global health challenge with limited treatment options and significant morbidity and mortality. This study demonstrates that intraparenchymal sustained-release DEX fibers improve motor recovery and mitigate systemic side effects compared to systemic corticosteroid use. These findings highlight the potential for targeted, localized DEX therapy as a minimally invasive alternative to DC and cranioplasty.
- Open Access
Controlled Release of Bone Morphogenetic Protein-2 Improves Motor Function After Traumatic Brain Injury in a Rat Model
Severe traumatic brain injury (TBI) is a life-threatening condition characterized by internal brain swelling and commonly treated using a two-stage surgical approach. The interval between surgeries, generally spaced weeks to months, is associated with secondary neurologic complications from leaving the brain unprotected. Hydrogels may reshape severe TBI treatment by enabling a single-stage surgical intervention, capable of being implanted at the initial surgery, remaining flexible to accommodate brain swelling, and calibrated to regenerate bone after brain swelling has subsided. The current study evaluated the use of a pentenoate-modified hyaluronic acid (PHA) polymer with thiolated devitalized tendon (TDVT) for calvarial bone regeneration in a rat TBI model. Additionally, PHA-TDVT hydrogels encapsulating microspheres containing bone morphogenetic protein-2 (BMP-2) were investigated to enhance bone regeneration. All hydrogel precursor formulations exhibited sufficient yield stress for surgical placement. The addition of TDVT to the crosslinked hydrogels increased the average compressive modulus. In vitro cell studies revealed that the PHA-TDVT hydrogel with the highest concentration of BMP-2 microspheres (i.e., PHA-TDVT+µ100) significantly improved calcium deposition and osteogenic gene expression. Minimal in vivo bone regeneration was observed for all hydrogel groups; however, BMP-2 microsphere addition fortuitously reduced motor skill impairment and brain atrophy. The PHA-TDVT+µ100 group had 2.8 times greater reach index and 2.3 times lower brain atrophy values compared to the negative control (p<0.05). Overall, hydrogels with controlled release of BMP-2 may provide neuroprotective benefits in TBI treatment. Future studies should explore BMP-2 delivery strategies to enhance both bone and brain recovery in rat TBI studies. Graphical Statement of Significance: Severe traumatic brain injury (TBI) is a life-threatening condition characterized by internal brain swelling and is commonly treated using a two-stage surgical approach. Complications associated with the two-stage treatment paradigm include secondary neurologic impairment, termed syndrome of the trephined (SOT). SOT is often reversible once the second surgery is performed, whereas a single-stage TBI treatment paradigm may avoid the occurrence of SOT altogether. Utilizing hydrogels comprised of pentenoate-modified hyaluronic acid and thiolated devitalized tendon encapsulating microspheres containing bone morphogenetic protein-2 (BMP-2), the current study demonstrated improvements in motor skill function and reductions in brain atrophy in a rat TBI model. The introduction of hydrogels with controlled release of BMP-2 as a neuroprotective strategy for TBI application offers a promising approach for single-stage TBI treatment.
Open AccessControlled Release of Bone Morphogenetic Protein-2 Improves Motor Function After Traumatic Brain Injury in a Rat Model
Severe traumatic brain injury (TBI) is a life-threatening condition characterized by internal brain swelling and commonly treated using a two-stage surgical approach. The interval between surgeries, generally spaced weeks to months, is associated with secondary neurologic complications from leaving the brain unprotected. Hydrogels may reshape severe TBI treatment by enabling a single-stage surgical intervention, capable of being implanted at the initial surgery, remaining flexible to accommodate brain swelling, and calibrated to regenerate bone after brain swelling has subsided. The current study evaluated the use of a pentenoate-modified hyaluronic acid (PHA) polymer with thiolated devitalized tendon (TDVT) for calvarial bone regeneration in a rat TBI model. Additionally, PHA-TDVT hydrogels encapsulating microspheres containing bone morphogenetic protein-2 (BMP-2) were investigated to enhance bone regeneration. All hydrogel precursor formulations exhibited sufficient yield stress for surgical placement. The addition of TDVT to the crosslinked hydrogels increased the average compressive modulus. In vitro cell studies revealed that the PHA-TDVT hydrogel with the highest concentration of BMP-2 microspheres (i.e., PHA-TDVT+µ100) significantly improved calcium deposition and osteogenic gene expression. Minimal in vivo bone regeneration was observed for all hydrogel groups; however, BMP-2 microsphere addition fortuitously reduced motor skill impairment and brain atrophy. The PHA-TDVT+µ100 group had 2.8 times greater reach index and 2.3 times lower brain atrophy values compared to the negative control (p<0.05). Overall, hydrogels with controlled release of BMP-2 may provide neuroprotective benefits in TBI treatment. Future studies should explore BMP-2 delivery strategies to enhance both bone and brain recovery in rat TBI studies. Graphical Statement of Significance: Severe traumatic brain injury (TBI) is a life-threatening condition characterized by internal brain swelling and is commonly treated using a two-stage surgical approach. Complications associated with the two-stage treatment paradigm include secondary neurologic impairment, termed syndrome of the trephined (SOT). SOT is often reversible once the second surgery is performed, whereas a single-stage TBI treatment paradigm may avoid the occurrence of SOT altogether. Utilizing hydrogels comprised of pentenoate-modified hyaluronic acid and thiolated devitalized tendon encapsulating microspheres containing bone morphogenetic protein-2 (BMP-2), the current study demonstrated improvements in motor skill function and reductions in brain atrophy in a rat TBI model. The introduction of hydrogels with controlled release of BMP-2 as a neuroprotective strategy for TBI application offers a promising approach for single-stage TBI treatment.
- Open Access
Comparing Imaging Biomarkers of Cerebral Edema after TBI in Young Adult Male and Female Rats
Traumatic brain injury (TBI) is one of the leading causes of death and disability worldwide. Cerebral edema following TBI is known to play a critical role in injury severity and prognosis. In the current study we used multimodal magnetic resonance imaging (MRI) to assess cerebral edema 24 hours after unilateral contusive TBI in male and female rats. We then directly quantified brain water content in the same subjects ex vivo . We found that both males and females had similarly elevated T 2 values after TBI compared with sham controls. Apparent diffusion coefficient (ADC) was more variable than T 2 and did not show significant injury effects in males or females. Brain water was elevated in male TBI rats compared with sham controls, but there was no difference between female TBI and sham groups. Notably, MRI biomarkers of edema were more closely correlated with brain water in male rats; female rats did not show any relationship between brain water and T 2 or ADC. These observations raise questions about the interpretation of radiological findings traditionally interpreted as edema in female TBI patients. A better understanding of sex differences and similarities in the pathophysiology of post-traumatic edema is needed to help improve patient management and the development of effective treatment strategies for men and women.
Open AccessComparing Imaging Biomarkers of Cerebral Edema after TBI in Young Adult Male and Female Rats
Traumatic brain injury (TBI) is one of the leading causes of death and disability worldwide. Cerebral edema following TBI is known to play a critical role in injury severity and prognosis. In the current study we used multimodal magnetic resonance imaging (MRI) to assess cerebral edema 24 hours after unilateral contusive TBI in male and female rats. We then directly quantified brain water content in the same subjects ex vivo . We found that both males and females had similarly elevated T 2 values after TBI compared with sham controls. Apparent diffusion coefficient (ADC) was more variable than T 2 and did not show significant injury effects in males or females. Brain water was elevated in male TBI rats compared with sham controls, but there was no difference between female TBI and sham groups. Notably, MRI biomarkers of edema were more closely correlated with brain water in male rats; female rats did not show any relationship between brain water and T 2 or ADC. These observations raise questions about the interpretation of radiological findings traditionally interpreted as edema in female TBI patients. A better understanding of sex differences and similarities in the pathophysiology of post-traumatic edema is needed to help improve patient management and the development of effective treatment strategies for men and women.
- 25 June 2021
- Published by Springer Nature
- p. 17-25
Prenatal Diagnosis of Fetal Cranial Anomalies
- 28 May 2021
- Published by SAGE Publications in Annals of Otology, Rhinology & Laryngology
- Vol. 131 (3) , 326-330
Microsurgical Management of Early Onset Alveolar Soft Part Sarcoma of the Oral Tongue: Case Report and Review of the Literature
Objectives: Alveolar soft part sarcoma is a rare subset of soft tissue sarcomas, typically presenting in subjects 15 to 35 years of age. Usual presentation sites are the trunk, extremities, and the head and neck. Subjects younger than 5 years are rarely affected. Methods: In this retrospective case report, we present a 16-month old male with a rapidly growing soft tissue mass of the anterior and posterior tongue, found to be alveolar soft part sarcoma. Results: The subject was treated with primary surgical resection and the resulting defect was reconstructed with a radial forearm free flap. Conclusions: To our knowledge, this is the youngest subject to have been diagnosed with alveolar soft part sarcoma. Surgical extirpation and microvascular reconstruction were successful, and the patient remains disease free 4 years post-operatively.
- 28 May 2021
- Published by SAGE Publications in Annals of Otology, Rhinology & Laryngology
- Vol. 131 (3) , 326-330
Microsurgical Management of Early Onset Alveolar Soft Part Sarcoma of the Oral Tongue: Case Report and Review of the Literature
Objectives: Alveolar soft part sarcoma is a rare subset of soft tissue sarcomas, typically presenting in subjects 15 to 35 years of age. Usual presentation sites are the trunk, extremities, and the head and neck. Subjects younger than 5 years are rarely affected. Methods: In this retrospective case report, we present a 16-month old male with a rapidly growing soft tissue mass of the anterior and posterior tongue, found to be alveolar soft part sarcoma. Results: The subject was treated with primary surgical resection and the resulting defect was reconstructed with a radial forearm free flap. Conclusions: To our knowledge, this is the youngest subject to have been diagnosed with alveolar soft part sarcoma. Surgical extirpation and microvascular reconstruction were successful, and the patient remains disease free 4 years post-operatively.
- 21 April 2021
- Published by SAGE Publications in Annals of Otology, Rhinology & Laryngology
- Vol. 131 (1) , 94-100
Outcomes and Utility of Intracranial Free Tissue Transfer
Objective: Complications associated with intracranial vault compromise can be neurologically and systemically devastating. Primary and secondary repair of these deficits require an air and watertight barrier between the intracranial and extracranial environments. This study evaluated the outcomes and utility of using intracranial free tissue transfer as both primary and salvage surgical repair of reconstruction. Methods: A retrospective review was performed of all subjects who underwent intracranial free tissue transfer as primary or salvage repair. Results: A total of 13 intracranial free tissue transfers were performed on 11 subjects: osteocutaneous radial forearm free flaps (n = 6), partial myofascial rectus abdominis flaps (n = 5), temporoparietal fascia flap (n = 1), and serratus anterior myofascial flap (n = 1). Primary reconstruction was performed on 4 subjects with the remaining being salvage repair. Indications for surgery included neoplasm (n = 6 of 11), ballistic trauma (n = 3 of 11), motor vehicle accident (n = 1 of 11), and infection (n = 1 of 11). Three subjects required additional surgical repair for CSF leak and pneumocephalus, with 2 subjects requiring an additional free tissue transfer at a different site. Conclusion: In our experience, free tissue transfer is an effective primary and salvage surgical technique in the reconstruction of complex intracranial problems.
- 21 April 2021
- Published by SAGE Publications in Annals of Otology, Rhinology & Laryngology
- Vol. 131 (1) , 94-100
Outcomes and Utility of Intracranial Free Tissue Transfer
Objective: Complications associated with intracranial vault compromise can be neurologically and systemically devastating. Primary and secondary repair of these deficits require an air and watertight barrier between the intracranial and extracranial environments. This study evaluated the outcomes and utility of using intracranial free tissue transfer as both primary and salvage surgical repair of reconstruction. Methods: A retrospective review was performed of all subjects who underwent intracranial free tissue transfer as primary or salvage repair. Results: A total of 13 intracranial free tissue transfers were performed on 11 subjects: osteocutaneous radial forearm free flaps (n = 6), partial myofascial rectus abdominis flaps (n = 5), temporoparietal fascia flap (n = 1), and serratus anterior myofascial flap (n = 1). Primary reconstruction was performed on 4 subjects with the remaining being salvage repair. Indications for surgery included neoplasm (n = 6 of 11), ballistic trauma (n = 3 of 11), motor vehicle accident (n = 1 of 11), and infection (n = 1 of 11). Three subjects required additional surgical repair for CSF leak and pneumocephalus, with 2 subjects requiring an additional free tissue transfer at a different site. Conclusion: In our experience, free tissue transfer is an effective primary and salvage surgical technique in the reconstruction of complex intracranial problems.